Cargando…

Soluble Endoglin as a Potential Biomarker of Nonalcoholic Steatohepatitis (NASH) Development, Participating in Aggravation of NASH-Related Changes in Mouse Liver

Nonalcoholic steatohepatitis (NASH) is characterized by hepatic steatosis with inflammation and fibrosis. Membrane endoglin (Eng) expression is shown to participate in fibrosis, and plasma concentrations of soluble endoglin (sEng) are increased in patients with hypercholesterolemia and type 2 diabet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Igreja Sá, Ivone Cristina, Tripska, Katarina, Hroch, Milos, Hyspler, Radomir, Ticha, Alena, Lastuvkova, Hana, Schreiberova, Jolana, Dolezelova, Eva, Eissazadeh, Samira, Vitverova, Barbora, Najmanova, Iveta, Vasinova, Martina, Pericacho, Miguel, Micuda, Stanislav, Nachtigal, Petr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731045/ https://www.ncbi.nlm.nih.gov/pubmed/33261044 http://dx.doi.org/10.3390/ijms21239021

Ejemplares similares

High Soluble Endoglin Levels Affect Aortic Vascular Function during Mice Aging
por: Nejmanová, Iveta, et al.
Publicado: (2021)

Long term effects of soluble endoglin and mild hypercholesterolemia in mice hearts
por: Vitverova, Barbora, et al.
Publicado: (2020)

Labetalol and soluble endoglin aggravate bile acid retention in mice with ethinylestradiol-induced cholestasis
por: Cristina Igreja Sá, Ivone, et al.
Publicado: (2023)

Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells
por: Tripska, Katarina, et al.
Publicado: (2022)

Atorvastatin Modulates Bile Acid Homeostasis in Mice with Diet-Induced Nonalcoholic Steatohepatitis
por: Lastuvkova, Hana, et al.
Publicado: (2021)

Carvedilol impairs bile acid homeostasis in mice: implication for nonalcoholic steatohepatitis
por: Lastuvkova, Hana, et al.
Publicado: (2023)

Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients
por: Víšek, J., et al.
Publicado: (2021)

Iron overload reduces synthesis and elimination of bile acids in rat liver
por: Prasnicka, Alena, et al.
Publicado: (2019)

A Novel Animal Model of Nonalcoholic Steatohepatitis (NASH): Hypoxemia Enhances the Development of NASH
por: Takayama, Fusako, et al.
Publicado: (2009)

Cell Autophagy in NASH and NASH-Related Hepatocellular Carcinoma
por: Udoh, Utibe-Abasi S., et al.
Publicado: (2022)

Nash vek /
por: Nappelʹbaum, Moisei Solomonovich, 1869-1958
Publicado: (1984)

Nash manifolds
por: Shiota, Masahiro
Publicado: (1987)

Modeling NASH and NASH-Induced Hepatocellular Carcinoma: Faster and Better
por: Hirsova, Petra
Publicado: (2021)

Development of the Rabbit NASH Model Resembling Human NASH and Atherosclerosis
por: Hayashi, Momoko, et al.
Publicado: (2023)

Multidrug Resistance-Associated Protein 2 Deficiency Aggravates Estrogen-Induced Impairment of Bile Acid Metabolomics in Rats
por: Alaei Faradonbeh, Fatemeh, et al.
Publicado: (2022)

From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
por: Gastaldelli, Amalia, et al.
Publicado: (2019)

Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH
por: Horn, Christian L., et al.
Publicado: (2021)

The burden of nonalcoholic steatohepatitis (NASH) in the United States
por: Tapper, Elliot B., et al.
Publicado: (2023)

Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment
por: Ilan, Yaron
Publicado: (2018)

Increased Expression of RUNX1 in Liver Correlates with NASH Activity Score in Patients with Non-Alcoholic Steatohepatitis (NASH)
por: Kaur, Savneet, et al.
Publicado: (2019)

The essential John Nash
por: Nash, John, et al.
Publicado: (2002)

Molecular Pathogenesis of NASH
por: Caligiuri, Alessandra, et al.
Publicado: (2016)

Natural history of NASH
por: Armandi, Angelo, et al.
Publicado: (2021)

Nonalcoholic steatohepatitis (NASH) is associated with cardiac remodeling and dysfunction
por: Simon, Tracey G., et al.
Publicado: (2017)

Exosomal microRNAs and Progression of Nonalcoholic Steatohepatitis (NASH)
por: Qi, Xiaoyan, et al.
Publicado: (2022)

The Emerging Role of Extracellular Vesicles and Autophagy Machinery in NASH—Future Horizons in NASH Management
por: Trifylli, Eleni-Myrto, et al.
Publicado: (2022)

Resveratrol modifies biliary secretion of cholephilic compounds in sham-operated and cholestatic rats
por: Dolezelova, Eva, et al.
Publicado: (2017)

Stability and perfection of nash equilibria
por: Damme, Eric
Publicado: (1991)

Immune and inflammatory pathways in NASH
por: Ganz, Michal, et al.
Publicado: (2013)

Natural History of NAFLD/NASH
por: Ekstedt, Mattias, et al.
Publicado: (2017)

Dr. Thomas Nash Reed
Publicado: (1870)

Letter from Dr. Nash
por: Hart, James A.
Publicado: (1875)

The role of the microbiome in NAFLD and NASH
por: Kolodziejczyk, Aleksandra A, et al.
Publicado: (2018)

Noninvasive Diagnosis of NAFLD and NASH
por: Piazzolla, Valeria Annarita, et al.
Publicado: (2020)

Pathophysiology of NASH in endocrine diseases
por: Gariani, Karim, et al.
Publicado: (2021)

The paradox of immunotherapy in NASH-HCC
por: Peng, Yao, et al.
Publicado: (2021)

Dr. Eugene B. Nash
Publicado: (1918)

The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH)
por: Mehta, Rohini, et al.
Publicado: (2016)

Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma
por: Kutlu, Ozlem, et al.
Publicado: (2018)

A new method to induce nonalcoholic steatohepatitis (NASH) in mice
por: Savari, Feryal, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1n9ef5eo3ajg41n42rrtkp2h7f